)
Visual
test
Lunai Bioworks
Lunai Bioworks (LNAI) investor relations material
Lunai Bioworks Q1 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q1 2026 earnings summary14 Nov, 2025
Executive summary
Achieved net income of $2.8M for Q3 2025, a significant improvement from a $44.2M net loss in Q3 2024, primarily due to the absence of prior year goodwill impairment and a gain from subsidiary bankruptcy.
Operating expenses decreased 94% year-over-year, driven by lower goodwill impairment and reduced general and administrative costs.
Completed the acquisition of BioSymetrics Inc. in April 2025, expanding AI-driven precision medicine capabilities.
Deconsolidated Gedi Cube B.V. following its bankruptcy, resulting in a $12M gain.
Financial highlights
Net income for Q3 2025 was $2.8M, compared to a net loss of $44.2M in Q3 2024.
Operating expenses fell to $3.3M from $53.3M year-over-year, mainly due to a $47.6M goodwill impairment in the prior year.
Cash increased to $624.8K as of September 30, 2025, up from $92.7K at June 30, 2025.
Working capital deficit improved to $18.9M from $28.1M sequentially.
Total assets were $7.0M and total liabilities $20.0M at quarter-end.
Outlook and guidance
Management is focused on streamlining operations around AI-driven neurology and oncology diagnostics and therapeutic development.
Additional funding is required to support ongoing operations and commercialization efforts; there is substantial doubt about the ability to continue as a going concern without new capital.
Funding received in fiscal 2026 will be used for obligations, product commercialization, clinical development, and working capital.
Detail the plan to secure fiscal 2026 funding
What is the impact of the Gümrükcü lawsuit dismissal?
How will the material weakness in controls be resolved?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- 6 FebPECO
Record 2025 occupancy and 7% Core FFO growth; 2026 targets 5.5% FFO growth and strong acquisitions. - 6 FebPROV
Q2 FY2026 net income rose 65% year-over-year, with higher margins and strong credit quality. - 6 FebNVDA
AI-driven digital twins and accelerated computing are set to revolutionize industrial design and manufacturing. - 6 FebCDP
2025 FFO/share rose 5.8% to $2.72, with strong leasing and investment; 2026 guidance signals more growth. - 6 FebCRI
Q1 2025 saw record revenue, a return to profit, and major new contracts in space technology. - 6 FebCRINet loss widened to 7.5m PLN in H1 2024 as revenue fell and R&D costs remained high.
- 6 FebCRINet loss deepened on lower sales and higher costs, but major new contracts and restructuring are underway.
- 6 FebEMBASSY
Record revenue, NOI, and distributions highlight strong growth and robust segment performance. - 6 FebCRIRevenue fell and losses deepened, but ESA contracts and R&D projects drive future prospects.
- 6 FebTUPRS
Net income reached TRY 29.5 billion, with strong dividends and a robust net cash position.
Next Lunai Bioworks earnings date
Q2 202613 Feb, 2026
Lunai Bioworks
Next Lunai Bioworks earnings date
Q2 202613 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Renovaro Inc. is a biotechnology company focused on developing advanced allogeneic cell and gene therapies. These therapies are designed to enhance immune system responses with the potential for long-term or life-long remission in some of the most challenging cancers, as well as the treatment or possible cure of serious infectious diseases, including HIV and Hepatitis B virus (HBV). The company leverages its proprietary platforms in gene and cell therapy to create therapeutic candidates aimed at hyper-stimulating the immune system to target and destroy cancer cells and virus-infected cells. Renovaro Inc. is headquartered in Los Angeles, California, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage